Home > others & > OTSSP167

OTSSP167

OTSSP 167,OTSSP-167

OTSSP167是一种高效的MELK(母体胚胎亮氨酸拉链激酶)抑制剂，IC50为0.41 nM。

目录号
EY0688
EY0688
EY0688
纯度
99.34%
99.34%
99.34%
规格
1 mg
5 mg
10 mg
原价
385
968
1400
售价
385
968
1400
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    OTSSP167 is a highly potent MELK (maternal embryonic leucine zipper kinase) inhibitor with IC50 of 0.41 nM.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0.005-0.1 μM

  • 动物实验

    1 mg/kg , 5mg/kg ,10 mg/kg, 20 mg/kg 口服处理

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Chung S, et al. Oncotarget, 2012, 3(12), 1629-1640.
    [2] Kuner R, et al. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl). 2013 Feb;91(2):237-48. doi: 10.1007/s00109-012-0949-1.

    分子式
    C25H28Cl2N4O2    		 分子量
    487.42    		 CAS号
    1431697-89-0    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    0.8 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01245855 Prostaglandin E1|Percutaneous Coronary Intervention Drug: lipo-PGE1 First Affiliated Hospital, Sun Yat-Sen University Phase 3 2011-01-01 2010-11-22
    NCT01776320 Erectile Dysfunction Drug: Alprostadil Lawson Health Research Institute Phase 4 2013-12-01 2014-03-03
    NCT02889822 Cardiovascular Diseases Drug: Alprostadil Liposomes for Injection Guangzhou Yipinhong Pharmaceutical CO.,LTD Phase 1 2010-03-01 2016-09-12
    NCT00619229 Macular Degeneration Drug: Alprostadil (prostaglandin E1)|Other: Placebo UCB Pharma Phase 3 2006-07-01 2014-10-17
    NCT02895373 Respiratory Distress Syndrome, Adult|Extracorporeal Membrane Oxygenation Drug: Alprostadil|Drug: 0.9% sodium chloride solution Thomas Staudinger|Medical University of Vienna Phase 2 2016-07-01 2016-09-12
    NCT00596752 Peripheral Arterial Occlusive Disease Drug: Alprostadil|Other: Placebo UCB BIOSCIENCES GmbH|Aptiv Solutions|UCB Pharma Phase 4 2004-03-01 2015-02-26
    NCT00733434 Microsurgery|Head and Neck|Prostaglandin E1|Thrombosis|Complications Drug: Prostaglandin E1|Other: Saline National Taiwan University Hospital Phase 4 2008-07-01 2009-10-26
    NCT02877173 Arteriosclerosis Obliterans Drug: Alprostadil Liposomes for Injection|Drug: Alprostadil Injection Guangzhou Yipinhong Pharmaceutical CO.,LTD Phase 2 2016-08-01 2017-03-08
    NCT02628106 Diabetic Nephropathy Drug: Lipo-PGE1 West China Hospital Phase 4 2015-12-01 2016-11-02
    NCT00598429 Infant, Newborn|Respiratory Insufficiency|Pulmonary Hypertension|Respiratory Distress Syndrome, Newborn|Streptococcal Infections Drug: Inhaled Prostaglandin E1 NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 2008-05-01 2016-12-08
    NCT01263925 Stage II Peripheral Arterial Occlusive Disease|Intermittent Claudication Fontaine Stage II PAOD Drug: Alprostadil (Prostaglandin E1)|Drug: Pentoxifylline|Drug: Placebo to Pentoxifylline oral|Drug: Placebo to Alprostadil (Prostaglandin E1) intravenous UCB Pharma Phase 3 2001-04-01 2014-10-17
    NCT00610051 Heart Failure Drug: Alprostadil Biopeutics Co., Ltd Phase 3 2012-12-01 2017-01-30
    NCT01810575 Erectile Dysfunction Drug: WC3036-11F/Alprostadil in Vehicle 2.5%|Drug: WC3036-12F/Alprostadil in Vehicle 0.5%|Drug: WC3036-13P/Vehicle Only 0.5% Warner Chilcott Phase 2 2013-02-01 2014-08-08
    NCT00314548 Adult Respiratory Distress Syndrome|Pulmonary Hypertension Drug: PGE1 (prostacyclin)|Drug: normal saline Aga Khan University|Medical Research Council, Pakistan 2006-05-01 2010-05-18
    NCT01467076 Prematurity|Respiratory Insufficiency|Pulmonary Hypertension|Respiratory Distress Syndrome, Newborn Drug: Aerosolized Normal Saline|Drug: Inhaled PGE1 NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 2011-11-01 2016-11-03
    NCT02350218 Evidence of Liver Transplantation Drug: Eglandin Asan Medical Center Phase 2 2015-03-01 2017-01-23
    NCT00324948 Sexual Dysfunction, Physiological Drug: Topical alprostadil (PGE-1) VIVUS, Inc. Phase 2 2004-09-01 2009-03-09
    NCT00053716 Peripheral Vascular Disease Drug: Liprostin [liposomal Prostaglandin E1] Endovasc Phase 2 2003-02-01 2007-03-06
    NCT02223949 Obesity|Labor Complications Device: Cook double balloon catheter|Drug: PGE1 tablet Hillel Yaffe Medical Center Phase 2|Phase 3 2014-10-01 2014-08-21

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：